Skip to main content
Premium Trial:

Request an Annual Quote

Stem Cell Sciences Shareholders Support Sale to StemCells

NEW YORK (GenomeWeb News) – Shareholders of UK-based Stem Cell Sciences have voted in favor of selling the firm's assets to Stem Cell Sciences.

The vote is the most recent step in SCS' plans to sell off its assets and delist from the AIM and Australian Securities Exchange.

The firms announced the nearly $5 million deal earlier this month.

The transaction will provide Palo Alto, Calif.-based StemCells, which is focused on developing tissue-derived cellular products for therapeutic uses, with cell-based drug discovery technologies. Among the products StemCells gains through the deal are automated systems for production and manipulation of stem and progenitor cells, gene insertion technology for drug screening and for applications in cell and gene therapy, the SC Proven media formulation and reagent business, and SCS' licensing deals with firms, such as Merck and Millipore.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.